Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA5A | P35218 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10872078 | 0.88 | TAS2R14 (0.40) | TAS2R14P2RX7CA2CA1CA5A | |
| SCHEMBL7191759 | 0.87 | TAS2R14 (0.42) | TAS2R14P2RX7CA2CA1CA5A | |
| SCHEMBL1198277 | 0.85 | TAS2R14 (0.41) | TAS2R14P2RX7CA2LMNAGAA | |
| SCHEMBL28918935 | 0.85 | P2RX7 (0.41) | TAS2R14P2RX7CA2LMNAGAA | |
| SCHEMBL29595462 | 0.85 | TAS2R14 (0.41) | TAS2R14P2RX7CA2LMNAGAA | |
| SCHEMBL10873508 | 0.83 | P2RX7 (0.44) | TAS2R14P2RX7LMNAGAAL3MBTL1 | |
| SCHEMBL14919637 | 0.83 | TAS2R14 (0.40) | TAS2R14P2RX7CA2CA1CA5A | |
| SCHEMBL5170650 | 0.83 | TAS2R14 (0.40) | TAS2R14P2RX7CA2LMNAGAA | |
| SCHEMBL30901313 | 0.83 | P2RX7 (0.44) | TAS2R14P2RX7LMNAGAAL3MBTL1 | |
| SCHEMBL1854326 | 0.83 | TAS2R14 (0.44) | TAS2R14P2RX7CA2CA1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843499-A | Diamine with asymmetric structure, high-performance polyimide, and preparation methods and applications thereof | 华南理工大学 | 2024-04-09 | — | — | CN | claimed |
| US-4079090-A | Preparation of trichloromethyl-trifluoro methyl-benzenes | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | claimed |
| CN-117623863-B | Method for synthesizing (R) - (-) -1, 3-butanediol by diketene one-step method | 万华化学集团股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| CN-118354999-A | Pyridazine-1 (6H) -6-oxo compound and preparation method and application thereof | 深圳信立泰药业股份有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-107739352-B | Material for electronic devices | 默克专利有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-117843499-A | Diamine with asymmetric structure, high-performance polyimide, and preparation methods and applications thereof | 华南理工大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-117623863-A | Method for synthesizing (R) - (-) -1, 3-butanediol by diketene one-step method | 万华化学集团股份有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11818951-B2 | Condensed cyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-11-14 | — | — | US | disclosed |
| WO-2023134698-A1 | PYRIDAZINE-1(6H)-6-OXO COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134698-A1 | PYRIDAZINE-1(6H)-6-OXO COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 深圳信立泰药业股份有限公司 | 2023-07-20 | — | — | WO | disclosed |
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | METABOMED LTD. (IL) | 2023-06-08 | — | — | US | disclosed |
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-04-11 | — | — | US | disclosed |
| EP-1192118-A1 | PROCESS FOR THE SYNTHESIS OF 1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL)ETHAN-1-ONE | Merck & Co., Inc. (US) | 2002-04-03 | — | — | EP | disclosed |
| US-6350915-B1 | FORMING A GRIGNARD REAGENT AND REACTION WITH ACETIC ANHYDRIDE | MERCK & CO., INC. | 2002-02-26 | — | — | US | disclosed |
| US-6326517-B1 | REACTIN AN AROMATIC COMPOUND WITH CARBON MONOXIDE AND AMMONIA | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-04 | — | — | US | disclosed |
| US-6268527-B1 | REACTING TRIFLUOROMETHYL SUBSTITUTED AROMATIC COMPOUND WITH CARBON MONOXIDE AND HYDROXY COMPOUND IN PRESENCE OF METAL COMPOUND AND PHOSPHINE DERIVATIVE TO PRODUCE TRIFLUOROMETHYL SUBSTITUTED BENZOIC ACID DERIVATIVE | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6255545-B1 | BROMINATION OF BENZENE, M-BIS/TRIFLUOROMETHYL/-WITH 1,3-DIBROMO-5,5-DIMETHYLHYDANTOIN OR BROMOSUCCINIMIDE IN THE PRESENCE OF ACETIC ACID AND SULFURIC ACID | MERCK & CO., INC. | 2001-07-03 | — | — | US | disclosed |
| WO-2001002326-A1 | PROCESS FOR THE SYNTHESIS OF (R)-1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL)ETHAN-1-OL BY ASYMMETRIC TRANSFER HYDROGENATION | MERCK & CO., INC. (US) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000076948-A1 | PROCESS FOR THE SYNTHESIS OF 1-(3,5-BIS(TRIFLUOROMETHYL)-PHENYL)ETHAN-1-ONE | MERCK & CO., INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| US-4079090-A | Preparation of trichloromethyl-trifluoro methyl-benzenes | BAYER AKTIENGESELLSCHAFT (DT) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174507-A1 | IMIDAZOLE 3-OXIDE DERIVATIVE BASED ACSS2 INHIBITORS AND METHODS OF USE THEREOF | ACSS2, ADSS2, GLS2 | TAS2R14 4159/4885P2RX7 3582/4885CA2 1152/4885 |
| US-20020042541-A1 | Process for producing bis( trifluoromethyl)benzaldehyde | BRPF1, PFAS, FLI1 | TAS2R14 4164/4885P2RX7 3400/4885CA2 454/4885 |
| US-11818951-B2 | Condensed cyclic compound and organic light-emitting device including the same | C1S, CCNE2, CCNE1 | TAS2R14 1397/4885P2RX7 3533/4885CA2 2490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.